Biotech · Private company · Malvern, PA, US
Venatorx Pharmaceuticals, Inc.
Track this companyFree. Adds Venatorx Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Cefepime/VNRX-5133 (taniborbactam)Phase 3 · Urinary Tract InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- MeropenemPhase 3 · Urinary Tract InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- cefepime-taniborbactamPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- VNRX-5133 + cefepimePhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- VNRX-5133 and VNRX-5022Phase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy SubjectsPHASE1 · COMPLETED · started Jun 29, 2021ClinicalTrials.gov NCT04951505 · fetched Nov 12, 2026
- Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract InfectionsPHASE3 · COMPLETED · started Aug 7, 2019ClinicalTrials.gov NCT03840148 · fetched Nov 12, 2026
- Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult SubjectsPHASE1 · COMPLETED · started Mar 14, 2019ClinicalTrials.gov NCT03870490 · fetched Nov 12, 2026
- VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal ImpairmentPHASE1 · COMPLETED · started Apr 6, 2018ClinicalTrials.gov NCT03690362 · fetched Nov 12, 2026
NIH awards10
- Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infectionsFiscal year 2025 · $117KNIH RePORTER 5R01AI160269-05 · fetched Nov 12, 2026
- Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infectionsFiscal year 2025 · $1MNIH RePORTER 5R44AI177015-03 · fetched Nov 12, 2026
- Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumanniiFiscal year 2025 · $1MNIH RePORTER 5R44AI181353-02 · fetched Nov 12, 2026
- Development of Therapeutic Products for Antibiotic Resistant BacteriaFiscal year 2025 · $275.8KNIH RePORTER 75N93020C00016-P00012-9999-1 · fetched Nov 12, 2026
- Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumanniiFiscal year 2024 · $1MNIH RePORTER 1R44AI181353-01A1 · fetched Nov 12, 2026
- Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious DiseasesFiscal year 2024 · $185.2KNIH RePORTER 272201600029C-P00026-9999-1 · fetched Nov 12, 2026
- Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious DiseasesFiscal year 2024 · $185.2KNIH RePORTER 272201600029C-P00026-9999-2 · fetched Nov 12, 2026
- Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infectionsFiscal year 2024 · $1.2MNIH RePORTER 5R01AI160269-04 · fetched Nov 12, 2026
- Discovery of antiviral inhibitors for the treatment of orthopoxvirus infectionsFiscal year 2024 · $300KNIH RePORTER 5R43AI179443-02 · fetched Nov 12, 2026
- Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosaFiscal year 2024 · $1MNIH RePORTER 5R44AI170331-03 · fetched Nov 12, 2026